|
WO2019048036A1
|
|
Substituted imidazoquinolines
|
|
IL252669D0
|
|
Agonistic tnf receptor binding agents
|
|
US2017266301A1
|
|
Particles comprising single stranded RNA and double stranded RNA for immunomodulation
|
|
WO2018133937A1
|
|
Engineered cells for inducing tolerance
|
|
WO2018054484A1
|
|
Bispecific trivalent antibodies binding to claudin 6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseases
|
|
AU2016201637A1
|
|
Identification of tumor-associated markers for diagnosis and therapy
|
|
CN109476761A
|
|
Excitability TNF receptor-binding agents
|
|
WO2017067592A1
|
|
Cytotoxic immunostimulating particles and uses thereof
|
|
WO2017067593A1
|
|
Methods and means for inducing an immune response
|
|
EP3322715A1
|
|
Peptide mimotopes of the cd3 t-cell co-receptor epsilon chain and uses thereof
|
|
AU2015201737A1
|
|
Identification of tumour-associated cell surface antigens for diagnosis and therapy
|
|
WO2016146174A1
|
|
Compositions and methods for diagnosis and treatment of cancer
|
|
WO2016128060A1
|
|
Predicting t cell epitopes useful for vaccination
|
|
WO2016112983A1
|
|
Cytokine fusion proteins
|
|
WO2016062323A1
|
|
Methods and compositions for diagnosis and treatment of cancer
|
|
AU2014298504A1
|
|
Tumor antigens for determining cancer therapy
|
|
EP3747465A1
|
|
Diagnosis and therapy of cancer involving cancer stem cells
|
|
EP3164156A1
|
|
Stabilised formulations of rna
|
|
AU2014202125A1
|
|
Identification of tumor-associated markers for diagnosis and therapy
|
|
US2017007776A1
|
|
Cannula, an injection or infusion device and methods of using the cannula or the injection or infusion device
|
